The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

US DEA tightens restrictions on painkiller prescriptions.....           UK MHRA approves Cbris Lifesciences? new facility.....           GlaxoSmithKline plans to build new health drink units in Andhra Pradesh, India.....           BioSpecifics? Xiaflex demonstrates efficacy in Phase 2a cellulite study.....           PSC Investments acquires sterile injectable facility from MIR.....           EMA agrees to review Basilea?s isavuconazole marketing authorization application.....           Lilly's Ixekizumab proves superior in Phase 3 Psoriasis studies.....           Pfizer initiates EAP for palbociclib in US.....           Sucampo signs exclusive global manufacturing and supply deal for lubiprostone.....           Dicerna issues multiple patents covering claims for dicer substrate siRNAs.....           Auxilium Pharmaceuticals achieves positive results from phase 2a study of CCH in patients with cellulite.....           BioLineRx Receives Notice of Allowance for US Patent on BL-7010 for Gluten Toxicity.....           DEA tightens opioid dispensing rules amid controversy over abuse.....           2014 has potential to exceed milestone year of 2009 for M&A action.....           Pfizer, BMS pad bright Q2 with new FDA nod for Eliquis.....           Answer to mystery of Ranbaxy 'settlement discussions' may be found in Texas.....           Talk gets fevered over whether Pfizer, J&J or Lilly might make a run at Cubist.....           Valeant, Ackman pass threshold to call pivotal Allergan meeting.....           FDA approves Eliquis for DVT and PE treatment.....           TB Alliance to receive drug candidate compounds from Novartis.....           Pernix Therapeutics acquires US rights For Treximet.....           FDA approves GSK?s Arnuity Ellipta to treat asthma in US.....           MorphoSys, Emergent BioSolutions to co-develop and commercialize ES414.....           Regeneus, Cryosite to jointly manufacture human stem cell products.....           FDA authorizes Kronus ZnT8Ab Elisa Assay for marketing.....           UK launches emergency research to help battle Ebola outburst.....           Mitsubishi Tanabe Pharma, Astrazeneca partner on diabetic nephropathy research.....           Lannett agrees to purchase two generic pharmaceutical products.....           Glenmark starts IND-enabling studies of new bispecific antibody.....           Paradigm collaborates with TESARO on molecular profiling.....           EISAI seeks approval to expand antiepilepsy agent Fycompa as adjunctive cure of primary generalised tonic-clonic seizures.....           Mylan, private equity, Indian pharmas to compete for cast-off GSK brands.....           GSK's Arnuity approval adds another rebuilding block to respiratory franchise.....           Massive Novo insulin plant aims to make more with less.....           Pfizer eyes Actavis in backup plan to another AstraZeneca bid.....           Hospira scores reprieve in lawsuit fighting FDA's generic Precedex nods.....           What keeps C-suite execs up at night? Brands, launches, and cutting costs.....           Lilly's strong results for psoriasis drug come on heels of data from Novartis.....           Recipharm to buy Corvette Pharmaceutical Services for $160m.....           US DoJ clears AstraZeneca?s clinical trial.....           FDA approves Lilly and Boehringer?s Basaglar insulin glargine injection.....           Mylan launches generic version of Precedex injection.....           Will Allergan bid for Salix as it looks to escape Valeant's clutches?.....           Depomed scores a win in its epic struggle to fend off Gralise copycats.....           Celgene's cost-sharing offer persuades NICE to about-face on Revlimid.....           Most of pharma's 2014 woes playing out as execs expected.....           Hospira threatens wholesale job cuts if FDA lets Precedex copies roll out.....           Price could be key for Sanofi's new Gaucher pill as it sets out against IV rivals.....           Don't worry about a hep C pricing war, analysts tell Gilead-watchers.....           Merck taps celeb chef to deliver diabetes message to Hispanics.....           Novartis agrees to acquire 15% stake in Gamida Cell.....           FDA approves Cerdelga for Type 1 Gaucher disease treatment.....           Novan?s Nitricil technology demonstrates efficacy against multi-drug resistant pathogens.....           Capsugel and Cardax to collaborate on development of proprietary Astaxanthin products.....           Axxess Pharma reports increased global sales.....           7-Keto supplement brand sold to InterHealth.....           Immune Targeting Systems and WCCT Global announce a new influenza A H1N1 virus to support the experimental human viral challenge model.....           Clinigen Group acquires Ethyol (amifostine) global rights from AstraZeneca.....           Big investors urge drugmakers to stop badmouthing biosimilars.....           DOJ clears AstraZeneca for a U.S. Brilinta takeoff.....           Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion.....           Merck seeking dismissal of Fosamax femur-fracture suits.....           Lilly, Boehringer score FDA backing for Lantus copy, but patent fight awaits.....           Allergan CFO's departure may signal strength, not weakness.....           Pfizer submits NDA for breast cancer treatment Palbociclib to FDA.....           Globavir seeks approval to develop new Ebola drug.....           EastGate augments sub-micron self-nanoemulsifying platform technology.....           MediciNova releases positive interim results of Phase IIa MN-166 study in opioid dependence.....           Fresenius Kabi launches Acetylcysteine Solution 10% in multiple doses.....           PharPoint Research wins project award from Otologic Pharmaceuticals.....           Provectus signs MoU with Sinopharm-CSIPI and Sinopharm A-THINK.....           Apricus Biosciences announces launch of topical treatment for erectile dysfunction vitaros in Germany by Hexal.....           Biogen's multiple sclerosis drug Plegridy gets FDA approval.....           Pragma Pharmaceuticals to re-launch once daily Moxatag.....           FDA grants fast track status for Agios' AG-221 to treat acute myelogenous leukemia.....           Japan's Chugai Pharmaceutical denies Roche takeover reports.....           Alabama Supreme Court redux: Pfizer can be sued for generic Reglan harms.....           Docs to FDA: Biosimilars should have different names than branded drugs.....           Should deal-needy Pfizer target antibiotics specialist Cubist?.....           Reckitt Benckiser chief ahead of the consumer health curve, analysts say.....           Biogen ready to steal market share with newly minted MS drug Plegridy.....           Stubborn Valeant powers ahead with extended Allergan buyout offer.....           Roche?s Avastin plus chemotherapy gets FDA approval for cervical cancer treatment.....           Mallinckrodt completes acquisition of Questcor Pharmaceuticals.....           Supernus receives FDA fast track designation for SPN-810.....           Acura provides update on FDA discussions on development of Aversion Hydrocodone with Acetaminophen tablet.....           Isis Pharmaceuticals earns $2m from advancement of ISIS-SMN.....           Neurovive continues enrollment in Phase II study on NeuroSTAT.....           CYIG signs strategic cooperation agreement with Xi'an Putian Pharmacy.....           Trevi Therapeutics gets two patents for Nalbuphine ER.....           Nodality announces US patent for single cell network profiling technology platform.....           ImmuDyne launches clinical study of patented beta glucan technology.....           Access Pharmaceuticals awarded Japan patent for MuGard and ProctiGard.....           Nuvilex reports combined results of the initial Phase 1/2 clinical trial and second Phase 2 clinical trial of Cell-in-a-Box.....           La Jolla secures notice of allowance from USPTO for modified Pectin to treat chronic inflammation.....           Roche's Avastin nabs quick FDA nod for cervical cancer use.....           Valeant, Pershing Square: Bring on the SEC insider trading probe.....           NICE Zytiga snub is 'plainly illogical,' critic says.....           You want a piece of Sovaldi, Roche? Not so fast.....           Bloomberg: Roche negotiating for rest of Chugai for $10B.....           AstraZeneca starts Phase III program for asthma drug tralokinumab.....           Miltenyi Biotec acquires gene therapy assets from Lentigen.....           Coherus' CHS-1420 meets primary endpoint in pivotal pharmacokinetic clinical study.....           FDA accepts to review Pfizer's BLA for meningococcal B vaccine candidate.....           Ligand signs license deal with Avion for Captisol.....           PuraMed completes first production of MigraPure gel.....           FDA grants fast track status for Agios's AG-221 to treat AML.....           FDA approves B. Braun's Nutrilipid 20% for parenteral nutrition therapy.....           The irrational rationale for cancer drug prices, with Novartis' Zykadia as exhibit A.....           Merck's sleep drug suvorexant overcomes hurdles to win FDA approval.....           InterMune takeover talk is tantalizing, but are investors too optimistic?.....           For sale: One Swiss biotech with an antibiotic and a low tax rate.....           Survival miss for Amgen's Kyprolis may hurt approval chances in Europe.....           Pfizer, Merck, pick up hefty vax sales bump with CDC nod in seniors.....           AstraZeneca releases top-line results from Phase III programme of lesinurad in gout patients.....           Allergan acquires worldwide rights of LiRIS program from TARIS Biomedical.....           RedHill Biopharma acquires option for Phase II pancreatic cancer drug RP101.....           Amgen issues voluntary recall of Aranesp (500 mcg) prefilled syringes outside US.....           Reprogenetics expands to Southeast with Miami facility.....           Ohr Pharmaceutical reports additional interim data from Phase II trial of Squalamine Eye Drops.....           Horizon Pharma gets USPTO issues additional notice of allowance for VIMOVO.....           BioCryst gets additional NIAID funding to advance development of BCX4430.....           TNI BioTech signs supplemental collaborative agreement with Hubei Qianjiang Pharmaceutical.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists
Latest News
Join the New Scientist Focus Group session on Tuesday 9th September, 2014, from 10.35 to 12.05 at the APS Pharm Sci conference 2014
Join the New Scientist Focus Group session on Tuesday 9th September, 2014, from 10.35 to 12.05 at the APS Pharm Sci conference 2014.  The session will include presentations from established and emerging scientists and will be chaired by Neda Yavari from AstraZeneca and Mei Wong from Pfizer. The session will be opened by Dr Claire Thompson who will talk on Translating Innovation into Medicine Claire is a Co-founder and Director at NanoScientium. NanoScientium fast-tracks nanotechnologies into products and profits, with a focus on the healthcare space. It provides business intelligence to investors, academic and industrial nanotechnology developers and large corporations to enable their investment, development and acquisition strategies. Prior to this Claire was Head of Research and Development with Oxford Pharmascience,  where she developed cutting edge technologies to enable medicines to be safer and easier to take.. Following Claire, is Dr Nikoletta Fotaki who is a senior lecturer in pharmaceutical sciences  from the University of Bath, who will talk on Predicting Performance in Paediatric Population; a Biopharmaceutics Perspective.  Nikoletta’s research and activities are focused on the development of in vitro screening tools and associated software for predicting oral absorption, the assessment of the impact of changes in drug substance properties and changes in the formulation process on bioavailability, animal models for predicting absorption, and in vitro-in vivo correlations/ in vitro-in vivo relations.. The third speaker is Dr Michael Cook from the University of Reading who will talk on Glycopolymer Hydrogels as Mucosa-Mimetic Materials. Michael is a teaching fellow, in the chemistry and pharmacy departments. His responsibilities include the overseeing of tutorials, workshops and lab classes. His research interests lie primarily in the development of pharmaceutical materials containing living cells or other bioactives.. Jay Poorna Reddy who is a Research Scientist at Bristol-Myers Squibb will complete the session with a talk on On-line Raman Spectroscopy for Monitoring Form Changes During High Shear Wet Granulation: Effect of Process Parameters and Binder Solutions Containing Polymeric Excipients. . The New Scientist Focus Group ( aims to highlight the wide range of opportunities available to new scientists within the pharmaceutical arena providing advice on potential career paths and supporting their development.. Each year they organise Industrial Insights, a two day event for undergraduate and postgraduate students exploring opportunities in the pharmaceutical industry.  Please join them in March/April 2015 when Industrial Insights will be hosted by Pfizer at their pharmaceutical sciences facilities in Kent. For more information please see: .
APS Blog - Brendan Gilmore 'Is the tide really turning on antibiotic research stagnation?'
. Last week, British Prime Minister David Cameron announced the launch of a Commission on Antimicrobial Resistance, the first global leader to declare the need for immediate global action to halt the rise of antibiotic resistance, promote public engagement, education and stewardship to arrest the global over-use of antibiotics and examine the economic and market barriers to global antibiotic research and development which have seen the last three decades of the ‘antibiotic era’ characterized by a dearth of research into new chemical diversity in the antibiotic arsenal, as major Big Pharma players exited the field and no new classes of antibiotics marketed for a quarter of a century. The Commission will be chaired by the world-renowned economist, Dr Jim O’Neill (former Chief Economist at Goldman Sachs and creator of the BRIC acronym to represent the four major developing economies Brazil, Russia, India and China which symbolize the decentralization of global economic power away from the G7 countries). The commission, hosted and funded by the Wellcome Trust, will produce a major international review, examining the broader issues of incentivizing the antibiotic drug pipeline, the economic issues surrounding antimicrobial resistance and improved use and stewardship of our existing antimicrobial agents. Quoting from the Wellcome Trust, the commission is tasked with examining the following themes:. the development, use and regulatory environment of antimicrobials, especially antibiotics, and explore how to make investments in new antibiotics more attractive to pharmaceutical companies and other funding bodies. the balance between effective and sustainable incentives for investment, and the need to conserve antimicrobial drugs so they can remain effective for as long as possible how governments and other funders can stimulate investment in new antimicrobials, and timeframes and mechanisms for implementation. increasing international cooperation and support for action by the international community, including much closer working with low- and middle-income countries on the issue”. Although the announcement has received a widespread welcome in the UK and beyond, the Prime Minister has received some criticism for appointing an economist (rather than a scientist, presumably) to chair the commission. However, the acknowledgement that the stagnation of antibiotic innovation on a scale which is failing to meet the demands of global antibiotic use in the face of mushrooming antibiotic resistance is primarily due to economic barriers is a critical one. Furthermore, as developing economies flourish, the rise in demand for antibiotics soars, supporting fledgling healthcare systems, agriculture-based economies and ageing populations. A commission chair with expert knowledge of BRIC and other emerging economies, themselves major global consumers of antibiotics and key targets for public educational and antimicrobial stewardship programmes, may yet prove a significant move. The commission commences its activities in the autumn, initially for a period of one year.. This establishment of the commission comes hot on the heels of the announcement that antibiotics, has been chosen as the challenge theme (as voted for by the British public) for the £10m Longitude Prize 2014. The challenge set for the Longitude Prize is to develop a cost-effective, accurate, rapid and easy-to-use test for bacterial infections to enable healthcare professionals across the globe to select and administer the right antibiotic for a particular infection, at the right time. Such point-of-care diagnostics will form the basis of strategies to curb the inappropriate use of antibiotic agents, protecting the limited arsenal of antimicrobial agents available against emerging antibiotic resistance. The challenge is open, as in the spirit of the original prize, to both amateur scientists and the professional scientific community to put forward ideas on how to solve it. The Longitude Prize, a £20,000 (today c. £2m) challenge established by an Act of Parliament, to find a practical solution that could find longitude accurate to half a degree (equivalent to 2 minutes), was awarded 300 years ago to John Harrison for his invention of the marine chronometer. John Harrison was a joiner and clockmaker with little formal education, whose invention allowed accurate global positioning and ensured Britain’s position as a naval super power. In parallel, John Hadley and Tobias Mayer perfected the apparatus and astronomical tables, which allowed longitudinal measurements via the lunar distance method. It can only be hoped that the prize will again give rise to more than one approach to solve the intractable problem of antimicrobial resistance. The Longitude Committee, led by Astronomer Royal Lord Martin Rees, are now finalizing the criteria for award of the £10 million prize, with proposals accepted from this autumn.. In May 2014, the Biotechnology and Biological Sciences Research Council (BBSRC) announced that combating antimicrobial resistance would become a key strategic priority, in line with the UK Department of Health Five Year Antimicrobial Resistance Strategy (2013-2018), calling for improved knowledge and understanding of antimicrobial resistance, conservation and stewardship of the efficacy of existing treatments and stimulation of the development of new antibiotics (and their alternatives), diagnostics and novel therapies. Also, in May 2014, the Royal Pharmaceutical Society’s Pharmaceutical Sciences Expert Advisory Panel (PS-EAP) published ‘New medicines, Better Medicines, Better Use of Medicines – A Guide to the Science Underpinning Pharmaceutical Practice’, highlighting the major challenges and opportunities faced when creating new medicines, improving existing medicines or ensuring better, safer use of medicines. In addition, the document makes seven recommendations for action arising from the challenges highlighted. Recommendation two of the guide is “stimulating new antimicrobial development and improving antimicrobial stewardship”.. So, clearly the political, societal and scientific will is behind the development of new antimicrobial drugs, education and stewardship for protection of those we have available and development of new therapies for infectious diseases. The crisis of antimicrobial resistance, leads to significant opportunities for the UK science and technology sector in leading the world in new antimicrobial agents and therapies and technologies aimed at point-of-care diagnosis of infection to facilitate appropriate, judicious use of antibiotics and other antimicrobial agents.. The APS microbiology and anti-infectives focus group seeks to be at the forefront of underpinning the importance of microbiology in the pharmaceutical sciences, public engagement on antimicrobial stewardship and providing a forum for the scientific discussion of cutting edge antimicrobials research and development in these exciting times for antimicrobial chemotherapy..
Contribute to a Round Table discussion on the development of a Manufacturing Classification System with speaker and contributors from Astra Zeneca, BMS and GSK.
. On Tuesday 9th September 2014; 16:20 to 17:50 at the APS Pharm Sci Conference 2014. Speaker: Gavin Reynolds (AZ). Co-chairs: Michael Leane (BMS), Kendal Pitt (GSK).. This roundtable session will introduce the concept of a drug product Manufacturing Classification System (MCS) based on processing route and seeks feedback from the wider pharmaceutical science community on the best way to apply it to practice. The MCS is intended as a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the Active Pharmaceutical Ingredient (API) and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing based on “ideal” ranges for API physical properties and therefore indicate how robust a manufacturing process is likely to be in relation to those properties.. The four classes proposed are:. Class I: Direct Compression Class II: Dry Granulation Class III: Wet Granulation Class IV: Other Technologies. Input from interested parties is needed to develop this concept. In particular, feedback is sought on what API properties are important when selecting or modifying materials to enable an efficient pharmaceutical manufacturing process.
Join the APS Pharm Sci Conference debate
Monday 8th September 7.00pm onwards. The APS Pharm Sci Conference is great for networking and this year there are more opportunities than ever. For example why not join the debate on Monday 8th September at 7.00pm in the De Havilland Club on the University campus? While getting your thoughts together on the topic ‘The role of universities in open innovation research: academic entrepreneurship or industrial exploitation?’ you can enjoy a light buffet and liquid refreshments (which may or may not help the thought process!) for just £10!. The event is sponsored by the University of Hertfordshire and the Stevenage Bioscience Catalyst and provides a great chance to make contacts from these two institutions, have some intellectual stimulation and network with conference participants. You can even adjourn to the bar afterwards to continue discussions!. You can either register for the Conference and this event or for the event by itself at
Follow us
Upcoming Events
APS PharmSci 2014
8 - 10 September 2014
MIBio 2014 - Stability of biopharmaceuticals- getting the chemistry right
30th September 2014
APS Board Meeting
14 - 15 October 2014
APS PharmSci 2015
7 - 9 September 2015
APS PharmSci 2016
5 - 7 September 2016
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.